

1 Kathleen S. O’Neill  
2 Joseph Chandra Mazumdar  
3 Brian E. Hanna  
4 Robert A. Lepore  
5 U.S. Department of Justice  
6 Antitrust Division  
7 450 Fifth Street, NW, Suite 8000  
8 Washington, DC 20530  
9 Tel: (202) 307-2931  
10 Fax: (202) 307-2874  
11 Email: kathleen.oneill@usdoj.gov  
12 Email: chan.mazumdar@usdoj.gov  
13 Email: brian.hanna2@usdoj.gov  
14 Email: robert.lepore@usdoj.gov

15 Tai Milder  
16 U.S. Department of Justice  
17 Antitrust Division  
18 450 Golden Gate Avenue, Room 10-0101  
19 Box 36046  
20 San Francisco, CA 94012  
21 Tel: (415) 934-5300  
22 Fax: (415) 934-5399  
23 Email: tai.milder@usdoj.gov

24 *Attorneys for Plaintiff United States of America*

25 **UNITED STATES DISTRICT COURT**  
26 **FOR THE NORTHERN DISTRICT OF CALIFORNIA**  
27 **SAN FRANCISCO DIVISION**

28 UNITED STATES OF AMERICA,

Plaintiff,

v.

VA PARTNERS I, LLC, et al.,

Defendants.

Case No. 16-cv-01672 (WHA)

**PLAINTIFF’S RESPONSE  
TO PUBLIC COMMENT**

**RESPONSE OF THE UNITED STATES TO  
PUBLIC COMMENT ON THE PROPOSED FINAL JUDGMENT**

Pursuant to the Antitrust Procedures and Penalties Act (“APPA”), 15 U.S.C. § 16(b)-(h), the United States hereby files the single public comment received concerning the proposed Final Judgment in this case and responds to this comment. After careful consideration of the comment, the United States continues to believe that the proposed Final Judgment provides an effective and appropriate remedy for the antitrust violations alleged in the Complaint. The United States will move the Court for entry of the proposed Final Judgment after the public comment and this response have been published in the *Federal Register* pursuant to 15 U.S.C. § 16(d).

**I. PROCEDURAL HISTORY**

On April 4, 2016, the United States filed a civil antitrust Complaint against VA Partners I, LLC, (“VA Partners I”), ValueAct Capital Master Fund, L.P. (“Master Fund”), and ValueAct Co-Invest International, L.P. (“Co-Invest Fund”) (collectively, “ValueAct” or “Defendants”), to remedy violations of Section 7A of the Clayton Act, 15 U.S.C. § 18a, commonly known as the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”).

Following the filing of the Complaint, the parties engaged in settlement discussions that culminated in a consensual resolution of this matter. On July 12, 2016, the United States filed a proposed Final Judgment, a Stipulation and Proposed Order, and a Competitive Impact Statement (“CIS”) that explains how the proposed Final Judgment is designed to apply an appropriate penalty for, and adequately restrain, Defendants’ HSR Act violations. (ECF No. 38, 39.) As required by the APPA, the United States published the proposed Final Judgment and CIS in the *Federal Register* on July 25, 2016. *See* 81 Fed. Reg. 48,450 (July 25, 2016). In addition, the United States ensured that a summary of the terms of the proposed Final Judgment and the CIS, together with directions for the submission of written comments, were published in *The Washington Post* and the *San Francisco Chronicle* on seven different days during the period of July 18, 2016 to July 24, 2016. *See* 15 U.S.C. § 16(c). The 60-day waiting period for public comments ended on September 23, 2016. One comment was received and is described below and attached as [Exhibit 1](#).

Case No. 16-cv-01672

PLAINTIFF’S RESPONSE TO PUBLIC COMMENT

1 **II. THE COMPLAINT AND PROPOSED SETTLEMENT**

2 The Complaint alleges that ValueAct violated the HSR Act by failing to comply with the  
3 Act’s premerger notification and reporting requirements in connection with its acquisition of  
4 voting securities of Halliburton Co. (“Halliburton”) and Baker Hughes Inc. (“Baker Hughes”) in  
5 2014 and 2015.

6 The HSR Act states that “no person shall acquire, directly or indirectly, any voting  
7 securities of any person” exceeding certain thresholds until that person has filed pre-acquisition  
8 notification and report forms with the Antitrust Division of the Department of Justice (“DOJ”)  
9 and the Federal Trade Commission (“FTC”) (collectively, the “Agencies”) and the post-filing  
10 waiting period has expired. 15 U.S.C. § 18a. A key purpose of the notification and waiting  
11 period is to protect consumers and competition from potentially anticompetitive transactions by  
12 providing the Agencies an opportunity to conduct an antitrust review of proposed acquisitions of  
13 voting securities exceeding certain thresholds before they are consummated.

14 As alleged in the Complaint and described further in the CIS, ValueAct made substantial  
15 purchases of stock in two direct competitors with the intent to participate in those companies’  
16 business decisions, without first complying with the notification and waiting period requirements  
17 of the HSR Act. Through these purchases, ValueAct simultaneously became one of the largest  
18 shareholders of both Halliburton and Baker Hughes. ValueAct established these positions as  
19 Halliburton and Baker Hughes – the second- and third-largest providers of oilfield services in the  
20 world – were being investigated for agreeing to a merger that threatened to substantially lessen  
21 competition in over twenty product markets in the United States. The United States filed a  
22 lawsuit to challenge the merger on April 6, 2016, and Halliburton and Baker Hughes abandoned  
23 the transaction a few weeks later. ValueAct’s failure to comply with the HSR Act risked the  
24 government’s ability to protect competition because it prevented the United States from  
25 reviewing in advance ValueAct’s stock acquisitions, which were made with the intent of  
26 participating in the companies’ business decisions and intervening with the management of each  
27 firm as necessary to increase the probability of the Halliburton-Baker Hughes merger being  
28 completed.

1 The Complaint alleges that Defendants could not excuse their failure to file the necessary  
2 notification and reporting forms by relying on the HSR Act's limited exemption for acquisitions  
3 made "solely for the purposes of investment" (the "investment-only exemption"). Section  
4 18a(c)(9) of the HSR Act exempts "acquisitions, solely for the purpose of investment, of voting  
5 securities, if, as a result of such acquisition, the securities acquired or held do not exceed 10 per  
6 centum of the outstanding voting securities of the issuer." As explained in the regulations  
7 implementing the HSR Act, voting securities are held "solely for the purpose of investment" if  
8 the acquirer has "no intention of participating in the formulation, determination, or direction of  
9 the basic business decisions of the issuer." 16 C.F.R. § 801.1(i)(1) ("HSR Rule 801.1(i)(1)").

10 As alleged in the Complaint, ValueAct did not qualify for the investment-only exemption  
11 because it intended from the time it purchased stock in these companies to participate in the  
12 business decisions of both companies. Specifically, ValueAct intended to use its position as a  
13 major shareholder of both Halliburton and Baker Hughes to obtain access to management; to  
14 learn information about the companies and the merger in private conversations with senior  
15 executives; to influence the decisions of these senior executives in a manner that increased the  
16 likelihood that Halliburton and Baker Hughes would be able to complete their anticompetitive  
17 merger; and ultimately to influence other business decisions regardless of whether the merger  
18 was consummated. The totality of the evidence, as described further in the Complaint,  
19 demonstrates that ValueAct was not entitled to claim the investment-only exemption.

20 The proposed Final Judgment provides for injunctive relief and the payment of civil  
21 penalties, which are designed to prevent future violations of the HSR Act. Specifically, the  
22 proposed Final Judgment prohibits Defendants from relying on the investment-only exemption if  
23 they intend to take, or their investment strategy identifies circumstances in which they may take,  
24 any of several specifically enumerated actions that reflect active participation in the company in  
25 which they are investing. The prohibited conduct provisions are aimed at deterring future HSR  
26 violations of the sort alleged in the Complaint. While this provision does not represent a  
27 comprehensive list of all conduct that would disqualify an acquirer of voting securities from  
28 relying on the investment-only exemption, it is aimed at deterring conduct that poses the greatest

1 threat to competition. The proposed Final Judgment also provides for compliance, access, and  
2 inspection procedures to promote Defendants' compliance with the proposed Final Judgment and  
3 to enable the United States to monitor such compliance. Finally, the proposed Final Judgment  
4 imposes an \$11 million civil penalty for Defendants' HSR Act violation. This penalty reflects  
5 the gravity of the conduct at issue and will adequately deter ValueAct and other companies from  
6 future HSR Act violations.

### 7 **III. STANDARD OF JUDICIAL REVIEW**

8 The APPA requires that proposed consent judgments in antitrust cases brought by the  
9 United States be subject to a sixty (60) day comment period, after which the court shall  
10 determine whether entry of the proposed Final Judgment is "in the public interest." 15 U.S.C. §  
11 16(e)(1). In making this public interest determination, the Court is required to consider:

12 (A) the competitive impact of such judgment, including  
13 termination of alleged violations, provisions for enforcement and  
14 modification, duration of relief sought, anticipated effects of alternative  
15 remedies actually considered, whether its terms are ambiguous, and any  
16 other competitive considerations bearing upon the adequacy of such  
17 judgment that the court deems necessary to a determination of whether the  
18 consent judgment is in the public interest; and

17 (B) the impact of entry of such judgment upon competition in  
18 the relevant market or markets, upon the public generally and individuals  
19 alleging specific injury from the violations set forth in the complaint  
20 including consideration of the public benefit, if any, to be derived from a  
21 determination of the issues at trial.

20 15 U.S.C. § 16(e)(1)(A) & (B).

21 The public interest inquiry is necessarily a limited one, as the United States is entitled to  
22 deference in crafting its antitrust settlements, especially with respect to the scope of its complaint  
23 and the adequacy of its remedy. *See generally United States v. Microsoft Corp.*, 56 F.3d 1448,  
24 1461 (D.C. Cir. 1995) (holding that government is entitled to "broad discretion to settle with the  
25 defendant within the reaches of the public interest"); *United States v. SBC Commc'ns, Inc.*, 489  
26 F. Supp. 2d 1, 10-11 (D.D.C. 2007) (assessing public interest standard under the Tunney Act);  
27 *United States v. US Airways Group, Inc.*, 38 F. Supp. 3d 69, 75 (D.D.C. 2014) (noting that the  
28 court's "inquiry is limited" because the government has "broad discretion" to determine the

1 adequacy of the relief secured through a settlement); *United States v. InBev N.V./S.A.*, No. 08-  
2 1965 (JR), 2009-2 Trade Cas. (CCH) ¶ 76,736, 2009 U.S. Dist. LEXIS 84787, at \*3, (D.D.C.  
3 Aug. 11, 2009) (noting that the court’s review of a consent judgment is limited and only inquires  
4 “into whether the government’s determination that the proposed remedies will cure the antitrust  
5 violations alleged in the complaint was reasonable, and whether the mechanism to enforce the  
6 final judgment are clear and manageable”).

7 Under the APPA, a court considers, among other things, the relationship between the  
8 remedy secured and the specific allegations set forth in the government’s complaint, whether the  
9 decree is sufficiently clear, whether enforcement mechanisms are sufficient, and whether the  
10 decree may positively harm third parties. *See Microsoft*, 56 F.3d at 1458-62. With respect to the  
11 adequacy of the relief secured by the decree, a court may not “engage in an unrestricted  
12 evaluation of what relief would best serve the public.” *United States v. BNS, Inc.*, 858 F.2d 456,  
13 462 (9th Cir. 1988) (quoting *United States v. Bechtel Corp.*, 648 F.2d 660, 666 (9th Cir. 1981));  
14 *see also Microsoft*, 56 F.3d at 1460-62; *United States v. Alcoa, Inc.*, 152 F. Supp. 2d 37, 40  
15 (D.D.C. 2001); *InBev*, 2009 U.S. Dist. LEXIS 84787, at \*3. Courts have held that:

16 [t]he balancing of competing social and political interests affected by a proposed antitrust  
17 consent decree must be left, in the first instance, to the discretion of the Attorney General.  
18 The court’s role in protecting the public interest is one of insuring that the government  
19 has not breached its duty to the public in consenting to the decree. The court is required  
20 to determine not whether a particular decree is the one that will best serve society, but  
21 whether the settlement is “within the reaches of the public interest.” More elaborate  
22 requirements might undermine the effectiveness of antitrust enforcement by consent  
23 decree.

24 *Bechtel*, 648 F.2d at 666 (emphasis added) (citations omitted).

25 Courts “may not require that the remedies perfectly match the alleged violations.” *SBC*  
26 *Commc’ns*, 489 F. Supp. 2d at 17. Rather, the ultimate question is whether “the remedies  
27 [obtained in the decree are] so inconsonant with the allegations charged as to fall outside of the  
28 ‘reaches of the public interest.’” *Microsoft*, 56 F.3d at 1461. Accordingly, the United States  
“need only provide a factual basis for concluding that the settlements are reasonably adequate  
remedies for the alleged harms.” *SBC Commc’ns*, 489 F. Supp. 2d at 17; *see also United States*

1 *v. Apple, Inc.*, 889 F. Supp. 2d 623, 631 (S.D.N.Y. 2012). And, a “proposed decree must be  
 2 approved even if it falls short of the remedy the court would impose on its own, as long as it falls  
 3 within the range of acceptability or is within the reaches of the public interest.” *United States v.*  
 4 *Am. Tel. & Tel. Co.*, 552 F. Supp. 131, 151 (D.D.C.1982) (citations and internal quotations  
 5 omitted); *see also United States v. Alcan Aluminum Ltd.*, 605 F. Supp. 619, 622 (W.D. Ky.  
 6 1985) (approving the consent decree even though the court would have imposed a greater  
 7 remedy).

8 In its 2004 amendments to the APPA,<sup>1</sup> Congress made clear its intent to preserve the  
 9 practical benefits of utilizing consent decrees in antitrust enforcement by adding the  
 10 unambiguous instruction that “[n]othing in this section shall be construed to require the court to  
 11 conduct an evidentiary hearing or to require the court to permit anyone to intervene.” 15 U.S.C.  
 12 § 16(e)(2). The procedure for the public interest determination is left to the discretion of the  
 13 court, with the recognition that the court’s “scope of review remains sharply proscribed by  
 14 precedent and the nature of Tunney Act proceedings.” *SBC Commc’ns*, 489 F. Supp. 2d at 11;  
 15 *see also United States v. Enova Corp.*, 107 F. Supp. 2d 10, 17 (D.D.C. 2000) (“[T]he Tunney Act  
 16 expressly allows the court to make its public interest determination based on the basis of the  
 17 competitive impact statement and response to public comments alone.”); *US Airways*, 38 F.  
 18 Supp. 3d at 76 (same).

#### 19 **IV. SUMMARY OF PUBLIC COMMENT AND RESPONSE OF THE UNITED** 20 **STATES**

21 During the 60-day comment period, the United States received one comment, from  
 22 Phillip Goldstein, manager of activist hedge fund Bulldog Investors. Mr. Goldstein does not  
 23 argue that the relief set forth in the proposed Final Judgment is inadequate to address the  
 24 allegations in the Complaint, nor does he assert that the terms of the decree should be altered in  
 25 any particular way. Instead, Mr. Goldstein claims that it “appears” that ValueAct settled this  
 26

---

27 <sup>1</sup> The 2004 amendments substituted “shall” for “may” when setting forth the relevant factors for courts to consider  
 28 and amended the list of factors to focus on competitive considerations and to address potentially ambiguous  
 judgment terms. *Compare* 15 U.S.C. § 16(e) (2004), *with* 15 U.S.C. § 16(e)(1) (2006); *see also SBC Commc’ns*,  
 489 F. Supp. 2d at 11 (concluding that the 2004 amendments “effected minimal changes” to Tunney Act review).

1 matter because the FTC increased the civil penalties for HSR violations and took the position  
2 that such increases could apply retroactively. Mr. Goldstein also claims that HSR Rule  
3 801.1(i)(1) – the FTC’s 1978 rule explaining the meaning of the “investment only” exemption –  
4 “irrationally” draws a distinction between passive and active investors and thus should be  
5 revised. Mr. Goldstein further claims that HSR Rule 801.1(i)(1) is unconstitutional because it  
6 violates the First Amendment. In light of these arguments, Mr. Goldstein urges the United States  
7 to seek a stay of this enforcement action until this rule is revised. As explained below, none of  
8 Mr. Goldstein’s arguments warrant delaying entry of the proposed Final Judgment.

9 First, as fully detailed in the CIS, the United States settled this case because it determined  
10 that the injunction and \$11 million penalty imposed on ValueAct was in the public interest  
11 because this relief adequately addresses and reflects the gravity of ValueAct’s wrongful conduct  
12 and will strongly deter ValueAct and other companies from violating the HSR Act. None of Mr.  
13 Goldstein’s arguments provide a basis for questioning, let alone, overruling the United States’  
14 broad discretion in reaching this determination.

15 Second, Mr. Goldstein’s passing reference to ValueAct’s supposed “coerced  
16 capitulation” in agreeing to settle this action misses the mark because the sole purpose of the  
17 Tunney Act review process is to determine why the Agencies – rather than a defendant – decided  
18 to settle a civil antitrust enforcement action and whether doing so was in the public interest.  
19 *Bechtel*, 648 F.2d at 666 (“The court’s role in [the Tunney Act review process] is one of insuring  
20 that the government has not breached its duty to the public in consenting to the decree . . . [and]  
21 to determine . . . whether the settlement is ‘within the reaches of the public interest.’”); *Inbev*,  
22 2009 U.S. Dist. LEXIS 84787, at \*3 (noting that the relevant inquiry during the Tunney Act  
23 review process is “whether the government’s determination that the proposed remedies will cure  
24 the antitrust violations alleged in the complaint was reasonable”). In any event, Mr. Goldstein’s  
25 assertion that ValueAct was purportedly forced to settle because the FTC increased the potential  
26 fines during the pendency of this action ignores the fact that the \$11 million fine that ValueAct  
27 agreed to pay was within the fine amount that the United States sought when it filed this action  
28 and that this amount was based on the penalties in effect *prior to* publication of the FTC’s



1 interim final rule on June 30, 2016. *See* Cmplt. ¶ 6 & Request for Relief.

2 Third, Mr. Goldstein’s lengthy argument that the distinction drawn in HSR Rule  
3 801.1(i)(1) between passive and active investors is “irrational” and should be revised is similarly  
4 outside the scope of this proceeding. As noted above, the court’s inquiry in a Tunney Act  
5 proceeding is limited to “whether the government’s determination that the proposed remedies  
6 will cure the antitrust violations alleged in the complaint was reasonable, and whether the  
7 mechanism[s] to enforce the final judgment are clear and manageable.” *InBev*, 2009 U.S. Dist.  
8 LEXIS 84787, at \*3. Mr. Goldstein’s assertions that HSR Rule 801.1(i)(1) – a rule that has been  
9 in effect for nearly thirty years – is “irrational” and should be revised are wholly irrelevant to the  
10 sole question before the Court: whether the proposed Final Judgment adequately addresses the  
11 harms alleged in the Complaint. In other words, Mr. Goldstein’s assertions are plainly outside  
12 the scope of the limited review that Congress established under the Tunney Act. To the extent  
13 Mr. Goldstein wishes to dispute the appropriateness of HSR Rule 801.1(i)(1) and how it is  
14 applied, he can direct his suggestions to the FTC (or could have commented when the rule was  
15 originally passed<sup>2</sup>). He cannot, however, use his general opposition to HSR Rule 801.1(i)(1) as a  
16 basis to reject or delay entry of the proposed Final Judgment.

17 Finally, Mr. Goldstein’s suggestion that this Court should reject the proposed Final  
18 Judgment because HSR Rule 801.1(i)(1) is “unconstitutional” has no merit. To the extent that  
19 this assertion – which has no bearing on whether the proposed Final Judgment adequately  
20 addresses the antitrust violations alleged in the Complaint – is properly before the Court, HSR  
21 Rule 801.1(i)(1) is content neutral and does not violate the First Amendment. Even if the rule  
22 implicated First Amendment interests, it would readily withstand review. *See Cableamerica*  
23 *Corp. v. FTC*, 795 F. Supp. 1082, 1093 (N.D. Ala. 1992) (dismissing claim that the FTC’s  
24 enforcement of the HSR Act’s reporting requirements violated the plaintiff’s First Amendment  
25 rights).

26 For all of these reasons, Mr. Goldstein’s public comment provides no basis to deny or  
27

---

28 <sup>2</sup> Contrary to Mr. Goldstein’s comment, the original revised HSR rules, including 16 C.F.R. § 801.1(i)(1), were  
subject to public comment prior to being adopted. *See* 42 Fed. Reg. 39040, 39047 (Aug. 1, 1977).

1 delay entry of the proposed Final Judgment.

2 **V. CONCLUSION**

3 After reviewing the public comment, the United States continues to believe that the  
4 proposed Final Judgment, as drafted, provides an effective and appropriate remedy for the  
5 antitrust violations alleged in the Complaint, and is therefore in the public interest. The United  
6 States will move this Court to enter the proposed Final Judgment after the comment and this  
7 response are published in the *Federal Register*.

8  
9 Date: October 17, 2016

Respectfully submitted,

10  
11 /s/ Kathleen S. O'Neill  
12 Kathleen S. O'Neill  
13 U.S. Department of Justice  
14 Antitrust Division  
15 450 5<sup>th</sup> St. NW, 8000  
16 Washington, DC 20530  
Tel: (202) 307-2931  
Fax: (202) 307-2784  
Email: kathleen.oneill@usdoj.gov